TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

TCR² Therapeutics (Nasdaq: TCRR), a clinical-stage cell therapy company, announced that CEO Garry Menzel will present an update on the company's progress at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 AM ET. The presentation will take place on a virtual platform, and a live webcast will be available on the company's Investors page. An archived replay will be accessible for at least 30 days following the event. TCR² focuses on developing novel T cell therapies for cancer patients targeting solid tumors.

CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that Garry Menzel, President and Chief Executive Officer of TCR² Therapeutics, will present an update on Company progress at the H.C. Wainwright BioConnect Conference on Monday, January 10^th at 7:00AM E.T. using a virtual platform.

A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.

About TCR² Therapeutics

TCR² Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC^®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR², please visit www.tcr2.com.

Investor and Media Contacts:

TCR² Therapeutics

Carl Mauch
Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com

FAQ

When will TCRR CEO Garry Menzel present at the H.C. Wainwright BioConnect Conference?

Garry Menzel will present on January 10, 2022, at 7:00 AM ET.

How can I watch the TCRR presentation at the BioConnect Conference?

The presentation can be viewed live on the Investors page of TCR² Therapeutics' website.

What is the focus of TCR² Therapeutics and its TCRR stock?

TCR² Therapeutics focuses on developing novel T cell therapies for cancer patients with solid tumors.

Will there be a replay available for TCRR's presentation?

Yes, an archived replay will be available for at least 30 days after the presentation.